| Sativex (nabiximols) / Jazz |
2016-000840-32: Clinical study about changes of bladder disorders in patients with multiple sclerosis treated with Sativex , using clinical examination and urodynamic evaluation. Studio dell¿andamento dei disturbi vescicali in pazienti con Sclerosi Multipla trattati con Sativex, tramite valutazione clinica ed esame urodinamico |
|
|
| Not yet recruiting | 4 | 40 | Europe | SATIVEX, Oromucosal spray, SATIVEX - SPRAY PER MUCOSA ORALE 3 FLACONI NEBULIZZATORI CON POMPA DOSATRICE DA 10 ML - 90 EROGAZIONI | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Allmirall | Multiple Sclerosis patients treated with nabiximols (Sativex¿, Almirall) Pazienti affetti da Sclerosi Multipla in trattamento con Sativex, Multiple Sclerosis patients treated with nabiximols (Sativex¿, Almirall) Pazienti affetti da Sclerosi Multipla in trattamento con Sativex, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-001777-31: Pilot study on the effect of cannabinoids THC + CBD on resistant spasticity in patients with chronic spinal cord injury. Estudio piloto sobre el efecto de los cannabinoides THC+CBD en la espasticidad resistente en pacientes con lesión medular crónica |
|
|
| Not yet recruiting | 4 | 20 | Europe | Sativex 2,7 mg / 2,5 mg Solución para pulverización bucal, Oral spray, suspension, Sativex 2,7 mg / 2,5 mg Solución para pulverización bucal | Hospital de Neurorrehabilitación Institut Guttmann, Almirall S.A. | Pilot study on the effect of THC+CBD cannabinoids on resistant spasticity in patients with chronic spinal cord injury. Estudio piloto sobre el efecto de los cannabinoides THC+CBD en la espasticidad resistente en pacientes con lesión medular crónica., Pilot study on the effect of THC+CBD cannabinoids on resistant spasticity in patients with chronic spinal cord injury. Estudio piloto sobre el efecto de los cannabinoides THC+CBD en la espasticidad resistente en pacientes con lesión medular crónica., Diseases [C] - Nervous System Diseases [C10] | | | | |
2004-003824-36: Randomized, double blind, parallel groups, placebo controlled pivotal clinical trial to asses preliminary efficacy and security of a sublingual Cannabis Standardized Extract (Sativex) added to reference treatment for prevention and treatment of nausea and late vomiting induced by moderately emetogenic chemotherapy. |
|
|
| Ongoing | 3 | 60 | Europe | delta9 tetrahidrocannabinol (THC) y cannabidiol (CBD), THC CBD, Sativex, Sativex | Fundació Institut Català de Farmacologia | Chemotherapy induced nausea and vomiting | | | | |
2006-001598-10: A double blind, randomised, placebo controlled, parallel group study of Sativex® in the treatment of subjects with pain due to diabetic neuropathy |
|
|
| Ongoing | 3 | 100 | Europe | Sativex, GW-1000-02, | GW Pharma Ltd | Diabetic Neuropathy | | | | |
2006-003655-20: A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia. |
|
|
| Ongoing | 3 | 50 | Europe | Sativex, GW-1000-02, | GW Pharma Ltd | Post-herpetic neuralgia symptom relief. | | | | |
2020-003271-18: A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis |
|
|
| Ongoing | 3 | 190 | RoW, Europe | Nabiximols - Sativex, Oromucosal spray, solution, Sativex Oromucosal Spray | GW Pharma Limited, GW Pharma Limited | Symptomatic treatment of spasticity in patients with multiple sclerosis (MS), Treatment of muscle spasm in patients with multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-004306-58: A study to asses the effects of Nabiximols on spasticity associated with multiple sclerosis. |
|
|
| Not yet recruiting | 3 | 575 | Europe | Nabiximols - Sativex, Oromucosal spray, solution | GW Pharma Limited, GW Pharma Ltd | Symptomatic treatment of spasticity in patients with MS, Multiple Sclerosis (MS), Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 3 | 139 | Europe, US, RoW | Nabiximols, GW-1000-02, Sativex, Placebo | Jazz Pharmaceuticals | Multiple Sclerosis (MS) | 02/23 | 02/23 | | |
ACTRN12611000398909: Double blind, randomised, placebo controlled trial of Sativex for the management of cannabis withdrawal |
|
|
| Not yet recruiting | 2 | 50 | | | University of New South Wales, National Health and Medical Research Council | Cannabis withdrawal | | | | |
2011-001739-21: A study of Sativex for pain Relief and appetite stimulation in Patients with advanced malignancy. Phase II Studio monocentrico di fase II per la valutazione degli effetti clinici ed immunologici dei Fitocannabinoidi sul dolore e sull’appettito nei pazienti oncologici in fase avanzata” |
|
|
| Ongoing | 2 | 188 | Europe | sativex, sativex | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\", Ricerca Corrente | advanced malignant cancer stato avanzato di cancro | | | | |
2016-001034-10: Neurophysiological assessment of the effect of Sativex to treat spasticity following stroke Valutazione neurofisiologica dell'effetto del Sativex sulla spasticità post-ictus |
|
|
| Ongoing | 2 | 50 | Europe | Sativex oromucosal spray, Oromucosal spray, SATIVEX - SPRAY PER MUCOSA ORALE 3 FLACONI NEBULIZZATORI CON POMPA DOSATRICE DA 10 ML - 90 EROGAZIONI | IRCCS-A.O.U. SAN MARTINO-IST, Almirall S.p.A Italia | Spasticity following stroke Spasticità a seguito di ictus, Spasticity following stroke Spasticità a seguito di ictus, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-004378-92: Study of the effect of cannabis in relieving the symptoms of endometriosis Estudio del efecto del canabis en el alivio de los síntomas de la endometriosis |
|
|
| Not yet recruiting | 2 | 10 | Europe | Sativex, Oromucosal spray, Sativex | Fundació Clínic per la Recerca Biomèdica, Almirall | Deep endometriosis Endometriosis profunda, Endometriosis Endometriosis, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-001056-17: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia |
|
|
| Not yet recruiting | 2 | 60 | Europe | Sativex Oromucosal Spray, Oromucosal spray, Sativex Oromucosal Spray | Kings's College London, South London and Maudsley NHS Foundation Trust, Alzheimer's Research UK | Clinically significant agitation in Alzheimer's Diseases, Clinically significant agitation in Alzheimer's Diseases, Psychiatry and Psychology [F] - Behaviours [F01] | | | | |
| Recruiting | 2 | 234 | Europe | Nabiximols, Sativex, Temozolomide, Nabiximols-matched placebo | University of Birmingham, University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals | Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent | 02/26 | 02/27 | | |
SENS-NMO, NCT05974293: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 2 | 44 | US | Nabiximols, Sativex, Placebo | Michael, Levy M.D.,Ph.D., Jazz Pharmaceuticals | NMO Spectrum Disorder, Spasticity, Muscle | 04/26 | 09/26 | | |
NCT05351801: Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain |
|
|
| Active, not recruiting | 2 | 21 | US | THC (Dronabinol), CBD (Epidolex), THC + CBD (Nabiximols), Placebo | VA Office of Research and Development | Diabetic Neuropathic Pain | 06/27 | 06/27 | | |
ACTRN12614000622606: Pilot Trial Proposal looking at the use of Cannabinoids for analgesia in chronic myocardial ischaemic chest pain, using Sativex Oromucosal Spray |
|
|
| Not yet recruiting | 1/2 | 10 | | | Dr Adrian Owen | Chronic Ischaemic Chest Pain | | | | |
2019-002786-35: Excretion and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis. Udskillelse og bivirkninger for tetrahydrocannabinol og cannabidiol (Sativex) hos patienter med nyreinsufficiens og patienter i dialyse. |
|
|
| Ongoing | 1/2 | 85 | Europe | Oromucosal spray, Sativex | Charlotte Uggerhøj Andersen, Aarhus University Hospital, Aarhus University, The Danish Regions, The Health Research Foundation of Central Denmark Region, Helsefonden, A.P. Møller Fonden, Nyreforeningen | Chronic kidney disease Kronisk nyreinsufficiens, Kidney disease Nyresygdom, Body processes [G] - Physiological processes [G07] | | | | |
2021-002318-15: A pharmacological trial with Sativex® and gentamicin for optimized pharmacological treatment of older patients with a focus on appetite stimulation and renal risk drugs |
|
|
| Not yet recruiting | 1/2 | 69 | Europe | Oromucosal spray, Concentrate for solution for injection/infusion, Hexamycin | Copenhagen University Hospital, Amager and Hvidovre, Department of Clinical Research, Udviklings- og Forskningspuljen, Fonden til Lægevidenskabens Fremme, Strategiske forskningsmidler Amager og Hvidovre Hospital, Region Hovedstadens Postdoc pulje, Sygehusapotekers Forsknings og Udviklings Pulje | Malnutrition, poor appetite, kidney function in older medical patients, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
CanPan, NCT05503147: Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients |
|
|
| Recruiting | 1 | 17 | Europe | Sativex, nabiximols | Ove Andersen, University Hospital Bispebjerg and Frederiksberg, North Denmark Regional Hospital, University of Copenhagen, Region Hovedstadens Apotek, Glostrup University Hospital, Copenhagen | Malnutrition, Anorexia, Cannabis, Aging, Emergency Service, Hospital, Renal Function, Pharmacokinetics | 08/23 | 09/23 | | |
| Not yet recruiting | N/A | 100 | | | Northern Alberta Renal Program, Northern Alberta Renal program | End stage renal disease, Chronic pain | | | | |